This clinical trial compares the side effects of intensity modulated proton therapy (IMPT) to volume modulated arc therapy (VMAT) for the treatment of patients with endometrial or cervical cancer. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill tumor cells and shrink tumors. Both IMPT and VMAT are types of radiation therapy; however, IMPT uses proton beams and VMAT uses photon beams. Radiation therapy for endometrial and cervical cancer, such as IMPT and VMAT, comes with a risk of side effects which can impact patient quality of life. Both IMPT and VMAT are associated with improving delivery of radiation therapy and sparing organs surrounding the cancer; however, a need remains to learn more about the side effects experienced from each approach. Researchers hope that by comparing the side effects of IMPT to VMAT they will be able to identify which approach may be safer and/or more tolerable in treating patients with endometrial or cervical cancer.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT07415681.
Locations matching your search criteria
United States
Maryland
Baltimore
Maryland Proton Treatment CenterStatus: Active
Contact: Elizabeth May Nichols
Phone: 410-328-6080
University of Maryland/Greenebaum Cancer CenterStatus: Active
Contact: Elizabeth May Nichols
Phone: 410-328-6080
Bel Air
UM Upper Chesapeake Medical CenterStatus: Active
Contact: Elizabeth May Nichols
Phone: 410-328-6080
Columbia
Central Maryland Radiation Oncology in Howard CountyStatus: Active
Contact: Elizabeth May Nichols
Phone: 410-328-6080
Easton
University of Maryland Shore Medical Center at EastonStatus: Active
Contact: Elizabeth May Nichols
Phone: 410-328-6080
Glen Burnie
UM Baltimore Washington Medical Center/Tate Cancer CenterStatus: Active
Contact: Elizabeth May Nichols
Phone: 410-328-6080
Largo
UM Capital Region Medical CenterStatus: Active
Contact: Elizabeth May Nichols
Phone: 410-328-6080
Towson
UM Saint Joseph Medical CenterStatus: Active
Contact: Elizabeth May Nichols
Phone: 410-328-6080
PRIMARY OBJECTIVE:
I. To compare patient reported acute gastrointestinal toxicity specifically grade 2 or higher diarrhea events between IMPT and VMAT for patients receiving pelvic nodal irradiation for newly diagnosed cervical and endometrial cancer.
SECONDARY OBJECTIVES:
I. To compare the incidence of grade 4 lymphopenia during radiation between IMPT and VMAT for patients receiving pelvic nodal irradiation for newly diagnosed cervical and endometrial cancer.
II. To compare lymphocyte nadir at first follow-up visit after completion of radiation.
III. To compare physician reported gastrointestinal (GI) outcomes between arms.
IV. To compare rates of treatment completion within scheduled time frame between arms.
V. To compare GI, genitourinary (GU) and hematologic grade 2 or higher late toxicity events between arms.
VI. To compare 2-year overall survival, local failure and distant failure between arms.
CORRELATIVE OBJECTIVES:
I. To assess mean dosimetric features of IMPT plans as well as VMAT plans.
II. To assess treatment planning time for IMPT and VMAT plans.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM I: Patients undergo IMPT over 25-28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo computed tomography (CT) and/or positron emission tomography (PET) throughout the study.
ARM II: Patients undergo VMAT over 25-28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT and/or PET throughout the study.
After completion of study treatment, patients are followed up at 1 month, 3 months, and then every 3 months for up to 2 years.
Trial PhaseNo phase specified
Trial Typetreatment
Lead OrganizationUniversity of Maryland/Greenebaum Cancer Center
Principal InvestigatorElizabeth May Nichols